
Pacira BioSciences, Inc. (PCRX) stock: analyst price target and their real reliability
📈 Pacira BioSciences, Inc. (PCRX) stock price
🎯 PCRX price target & analyst consensus — price $25.83
⭐ The most reliable of them, either direction: HC Wainwright & Co. — 61% of its targets hit on this sector (321 calls tested). It aims for $38 (+47 %), call made on July 2, 2026, maturing on July 2, 2027 (57 d ago).
All 90 calls, one by one, with our verdict on each firm.
→ See all 90 targets, analyst by analystTheir real reliability on PCRX, firm by firm: who was right, who was wrong.
→ See their reliability on PCRX🔎 Detailed analyses
🏛️ Which US Congress members hold Pacira BioSciences, Inc. (PCRX)?
✅ Historical analyst reliability on PCRX
Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.
| Firm ↕ | % right i ↕ | Gain vs sector i ↕ | Calls i ↕ |
|---|---|---|---|
| SVB Leerink | 100% | +84.2% | 2 |
| B of A Securities ↗ | 100% | +37.2% | 2 |
| Jefferies ↗ | 71% | +57.3% | 14 |
| Wedbush ↗ | 50% | +53.8% | 10 |
| Northland Capital Markets ↗ | 50% | +50.2% | 2 |
| Raymond James ↗ | 50% | -16.4% | 2 |
| Needham ↗ | 37% | -2.6% | 27 |
| Piper Sandler ↗ | 33% | +16.6% | 9 |
| Truist Securities ↗ | 33% | -46.4% | 3 |
| HC Wainwright & Co. ↗ | 32% | -6.7% | 22 |
See the other 6 firms
| JP Morgan ↗ | 0% | -52.7% | 2 |
| JMP Securities | 0% | -25.1% | 3 |
| Mizuho ↗ | 0% | -20.2% | 2 |
| RBC Capital ↗ | 12% | -31.5% | 8 |
| Barclays ↗ | 27% | +14.6% | 15 |
| Canaccord Genuity ↗ | 29% | -17.6% | 7 |
📊 What $1,000 invested in Pacira BioSciences, Inc. would be worth › open the full page
If I'd invested $1,000 in Pacira BioSciences, Inc.
| Investment | Worth today | Gain |
|---|---|---|
| 1 years ago | $1,327 | +33% |
| 3 years ago | $648 | -35% |
| 5 years ago | $418 | -58% |
Return by year (Pacira BioSciences, Inc.)
| Year | Return | $1,000 invested at year start |
|---|---|---|
| 2026 (YTD) | -3% | $966 (-3%) |
| 2025 | +37% | $1,327 (+33%) |
| 2024 | -44% | $741 (-26%) |
📰 Recent news on Pacira BioSciences, Inc.
📋 All analyst calls on PCRX
matures : Aug 5, 27
matures : Aug 5, 27
matures : Jul 1, 27
matures : May 1, 27
matures : May 1, 27
matures : Mar 26, 27
matures : Jan 9, 27
matures : Jan 9, 27
See the other 82 calls, newest to oldest
matures : Dec 9, 26
matures : Nov 7, 26
matures : Jan 30, 26
matures : Jan 14, 26
matures : Nov 12, 25
matures : Nov 7, 25
matures : Oct 4, 25
matures : Aug 12, 25
matures : Jul 3, 25
Frequently asked questions
Should I buy Pacira BioSciences, Inc. stock?
This isn't buy advice. For Pacira BioSciences, Inc., the analyst consensus is "Buy", with an average price target of $29.00 (+12% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (2 calls tracked on Pacira BioSciences, Inc.). We show the numbers — you decide.
Is it too late to buy Pacira BioSciences, Inc.? How high can it go?
The most bullish analyst target on Pacira BioSciences, Inc. is $38.00 (+47% above today's price); the average is $29.00. That's the upside they see. Check how reliable those analysts have actually been on Pacira BioSciences, Inc. on our site before trusting it.
Is Pacira BioSciences, Inc. still a good buy?
The most useful "opinion" isn't an opinion — it's a track record: 16 analysts have a real record on Pacira BioSciences, Inc., the best hitting 100% over 2 calls. Current consensus: "Buy". Make your call on data, not noise.
What has Pacira BioSciences, Inc.'s past performance been?
Historical returns and a "how much if I had invested" calculator: PCRX performance & returns.
What is the best month to buy PCRX?
The 12 months ranked by the stock's past returns: best & worst month to buy PCRX.